Understanding and supporting automated insulin delivery use in a diverse population with type 2 diabetes

Diabetes technologies can improve clinical outcomes and quality-of-life, yet people from ethnic minority and/or low-income groups are much less likely to use this technology than white, more affluent people. This is partly because people from ethnic minority and/or low-income groups have often been under-represented in clinical trials of diabetes technologies and accompanying qualitative research. Preliminary trials of closed-loop system use in adults with type 2 diabetes (T2D) have shown promising results and a large multi-centre study is now in set-up. To ensure the results and accompanying recommendations are not skewed towards white, more affluent people, we will use a variety of strategies, informed by our PPI group, to achieve good representation of people from ethnic minority and/or low-income groups in the trial and our proposed qualitative work. We will explore participants' experiences of using the closed-loop system, prioritising those from seldom-heard groups, so we can better understand the benefits (and challenges) to using the technology in people living with T2D, a condition that disproportionately affects those from ethnic minority and/or low-income groups. This will allow us to make recommendations for roll-out, and training and support packages, which are applicable to everyone who might benefit from the technology in the future.